A deal-hungry Vertex ushers in three more gene editing programs as it closes out harbinger CRISPR deal
Back in 2015, Vertex made a splash in the nascent CRISPR gene editing world by wagering $105 million to partner with one of its pioneers — then-private startup CRISPR Therapeutics — to generate up to six new treatments for genetic diseases.
Fast forward four years, the duo has accomplished the historic feat of dosing their ex vivo therapy, CTX001, in patients with beta thalassemia, and Vertex has clearly signaled its intent on going bigger into gene editing tech. As they wrap up the research part of their collaboration, the big biotech is tapping three more CRISPR programs for its pipeline, which has ballooned in recent weeks with new drugs introduced from new pacts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
